MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $129.06M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 0.97M
Average 0.95M
MXCT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
MaxCyte, Inc.NASDAQ: MXCT
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit declines year over year
Q1 FY2026 gross profit of $7.07M fell 20.5% year over year, behind the -14.5% change in trailing-twelve-month gross profit. Sequentially, it rose 24.2% from the prior quarter. Over 3 fiscal years it compounded at -11.9% a year.
Context
- Gross profit amounted to 81.2% of revenue in FY2025, down 0.5 pp from a year earlier.
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.5% toward the trailing-twelve-month pace of -14.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 26.8M USD
- Year-over-year change
- -15.0%
- 4-year CAGR
- -3.0%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.8M | -15.0% |
| FY2024 | 2024-12-31 | 31.53M | -13.7% |
| FY2023 | 2023-12-31 | 36.55M | -6.7% |
| FY2022 | 2022-12-31 | 39.16M | +29.5% |
| FY2021 | 2021-12-31 | 30.25M | — |
Gross Profit vs competitors
How MXCT compares with its peers on the latest reported figures
- MXCT's LTM Mar 2026 gross profit of $26.06M is the 6th highest of the 11 companies compared; the peer median is $19.78M.
- Its year-over-year change of -14.5% is the 6th highest of 11, against a peer median of -11.4%.
- Gross profit amounts to 80.7% of revenue for MXCT, versus a peer median of 71.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $66.34M | +249.9% | +138.0% | 58.3% | |
| LTM Mar 2026 | $54.45M | +23.4% | +31.9% | 50.9% | |
| LTM Mar 2026 | $38.18M | +38.8% | +55.6% | 85.1% | |
| LTM Mar 2026 | $34.56M | -45.8% | -31.5% | 100.0% | |
| LTM Mar 2026 | $26.15M | -3.4% | +10.8% | 45.3% | |
| LTM Mar 2026 | $26.06M | -14.5% | -11.9% | 80.7% | |
| LTM Mar 2026 | $13.41M | +43.6% | +56.6% | 71.1% | |
| LTM Mar 2026 | $2.14M | -35.6% | — | 72.2% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $523K | -60.4% | — | 28.3% |
| LTM Mar 2026 | -$3.03M | -150.0% | — | 489.8% | |
| LTM Dec 2025 | -$12.79M | -19.4% | — | 98.2% | |
| Peer median (excluding MXCT) | $19.78M | -11.4% | +43.8% | 71.6% | |
Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.89M | 44.26M | 41.29M | 38.63M | 33.03M |
| Cost of Revenue | 3.65M | 5.1M | 4.74M | 7.1M | 6.22M |
| Gross Profit | 30.25M | 39.16M | 36.55M | 31.53M | 26.8M |
| Gross Margin | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Research & Development | 15.41M | 19.51M | 23.82M | 22.23M | 20.82M |
| Selling, General & Admin | 31.68M | 44.48M | 57.04M | 56.35M | 47.04M |
| Operating Expenses | 48.44M | 66.52M | 84.85M | 82.72M | 72.09M |
| Depreciation & Amortization | 1.42M | 2.7M | 4.17M | 4.79M | 5.14M |
| EBITDA | (16.61M) | (20.75M) | (33.75M) | (36.27M) | (39.49M) |
| EBITDA Margin | -49.0% | -46.9% | -81.7% | -93.9% | -119.6% |
| Operating Income | (18.19M) | (27.36M) | (48.3M) | (51.2M) | (45.29M) |
| Operating Margin | -53.7% | -61.8% | -117.0% | -132.5% | -137.1% |
| Interest Income | 150.8K | 3.92M | 10.38M | 10.14M | 7.27M |
| Interest Expense | 1.04M | 126.9K | 0 | 0 | 0 |
| Other Income / Expenses | (893.6K) | 3.79M | 10.38M | 10.14M | 655K |
| Income Before Tax | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Pre-Tax Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Net Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| EPS (Basic) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| EPS (Diluted) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| Weighted Avg Shares | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
| Weighted Avg Shares (Diluted) | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.